TScan Therapeutics, Inc. (TCRX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer. The company is classified as an emerging growth company and a smaller reporting company. Its lead product candidate, TSC-101, is in Phase 1 clinical development for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients undergoing allogeneic hematopoietic cell transplantation (HCT).
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $982 | $2,171 |
| Net Loss | $(28,666) | $(34,127) |
| Net Loss Per Share (Basic & Diluted) | $(0.22) | $(0.26) |
| Operating Expenses | $30,121 | $38,421 |
| Cash and Cash Equivalents (End of Period) | $128,057 | $152,406 |
| Long-Term Debt | $32,654 | $32,534 |
| Accumulated Deficit | $(533,528) | $(504,862) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration and license revenue decreased by $1.19 million (55%) to $0.98 million, primarily due to the timing of research activities under the Amgen collaboration agreement.
- Expense Reduction: Total operating expenses decreased by $8.3 million (22%). Research and Development (R&D) expenses dropped $7.9 million, driven by a $5.2 million decrease in laboratory supplies and a $1.0 million decrease in facility-related costs. This reduction aligns with a strategic decision in November 2025 to prioritize the hematologic program and pause enrollment in the solid tumor Phase 1 trial.
- Improved Net Loss: Net loss narrowed by $5.5 million to $28.7 million, reflecting the reduction in operating expenses.
- Cash Flow: Net cash used in operating activities improved to $24.3 million from $37.6 million in the prior year period.
Outlook, Management Commentary, and Risks
- Liquidity: Management expects existing cash and cash equivalents ($128.1 million) to fund operations into the second half of 2027.
- Strategic Prioritization: The company reduced its workforce by approximately 30% (66 roles) in November 2025 to focus resources on the heme malignancy program (TSC-101, TSC-102-A01, TSC-102-A03) and paused the solid tumor trial.
- Debt Obligations: The company holds a $52.5 million term loan facility with Silicon Valley Bank (SVB), with $32.5 million funded. The loan matures in 2029 (or 2028 if milestones are not met) and includes an exit fee of 5% of the principal. The agreement contains restrictive covenants limiting asset disposal, additional indebtedness, and equity repurchases.
- Risks: Key risks include the need for substantial additional capital to complete development, the uncertainty of clinical trial outcomes, reliance on third-party manufacturers, and potential impacts from global economic uncertainty and trade tariffs.
Investor Verification Checklist
- Verify the sufficiency of the $128.1 million cash balance to fund operations through the second half of 2027 given the burn rate.
- Review the specific milestones required to extend the SVB loan maturity to 2029 and avoid early amortization.
- Monitor the progress of the TSC-101 registrational path following the End-of-Phase 1 meeting with the FDA.
- Assess the impact of the 30% workforce reduction on the company's ability to execute its prioritized clinical programs.
- Track the timing and recognition of revenue from the Amgen collaboration agreement.